...
首页> 外文期刊>Endocrine pathology >Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results.
【24h】

Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results.

机译:神经内分泌肿瘤引起肢端肥大症的异位生长激素释放激素分泌:长期随访结果。

获取原文
获取原文并翻译 | 示例

摘要

Ectopic secretion of growth hormone-releasing-hormone (GHRH) is a rare cause of acromegaly-representing less than 1% of patients. A 25-year-old woman was admitted to the hospital with acromegaly and a 6 x 6 cm infrahepatic mass. Sellar magnetic resonance imaging indicated diffuse pituitary enlargement consistent with hyperplasia. The infrahepatic mass was resected, and the histopathological diagnosis was a well-differentiated invasive neuroendocrine carcinoma of the duodenum with metastases to local lymph nodes. The tumor cells contained cytoplasmic immunoreactivity for GHRH. Because increased IGF-1 concentrations persisted after the operation, the patient was treated with octreotide long-acting repeatable (LAR) injections of 20 mg/month. Growth hormone and IGF-1 levels normalized. After 6 years of surveillance, a left paraaortic mass was detected by uptake of indium 111 octreotide. Surgical exploration revealed metastatic neuroendocrine carcinoma in a 2.5-cm lymph node. Postoperatively, the IGF-1 concentration was mildly elevated. Octreotide LAR therapy is being continued at 10 mg/month. This case suggests that octreotide treatment may have a beneficial effect on disease course and can be maintained for as long as 7 years in a patient with acromegaly due to a GHRH-secreting neuroendocrine carcinoma.
机译:生长激素释放激素(GHRH)的异位分泌是肢端肥大症的罕见原因,占不到1%的患者。一名25岁的妇女因肢端肥大症和6 x 6厘米的肝下肿块入院。鞍核磁共振成像表明垂体弥漫性垂体增大与增生相符。切除肝下肿物,并且组织病理学诊断为十二指肠的高分化浸润性神经内分泌癌,转移至局部淋巴结。肿瘤细胞含有对GHRH的细胞质免疫反应性。由于手术后IGF-1浓度持续升高,因此该患者接受了奥曲肽20毫克/月的长效重复性(LAR)注射治疗。生长激素和IGF-1水平恢复正常。监测6年后,通过摄取111奥曲肽铟检测到左腹主动脉肿块。手术探查发现在2.5厘米的淋巴结中有转移性神经内分泌癌。术后,IGF-1浓度轻度升高。奥曲肽LAR治疗正在以10 mg /月的速度继续进行。这种情况表明,奥曲肽治疗可能会对疾病进程产生有益影响,并且由于分泌GHRH的神经内分泌癌,在肢端肥大症患者中奥曲肽治疗可以维持长达7年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号